Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 4
2014 8
2015 8
2016 11
2017 22
2018 52
2019 73
2020 64
2021 25
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 28893920

234 results
Results by year
Filters applied: . Clear all
Page 1
Are SGLT2 Inhibitors Ready for Prime Time for CKD?
Pecoits-Filho R, Perkovic V. Pecoits-Filho R, et al. Clin J Am Soc Nephrol. 2018 Feb 7;13(2):318-320. doi: 10.2215/CJN.07680717. Epub 2017 Sep 11. Clin J Am Soc Nephrol. 2018. PMID: 28893920 Free PMC article. Review. No abstract available.
Sweet success? SGLT2 inhibitors and diabetes.
Layton AT. Layton AT. Am J Physiol Renal Physiol. 2018 Jun 1;314(6):F1034-F1035. doi: 10.1152/ajprenal.00557.2017. Epub 2017 Dec 27. Am J Physiol Renal Physiol. 2018. PMID: 29357429 Free PMC article. No abstract available.
Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.
Kobayashi K, Toyoda M, Kaneyama N, Hatori N, Furuki T, Sakai H, Takihata M, Umezono T, Ito S, Suzuki D, Takeda H, Kanamori A, Degawa H, Yamamoto H, Machimura H, Mokubo A, Chin K, Obana M, Hishiki T, Aoyama K, Nakajima S, Umezawa S, Shimura H, Aoyama T, Miyakawa M. Kobayashi K, et al. J Diabetes Res. 2019 Nov 3;2019:9415313. doi: 10.1155/2019/9415313. eCollection 2019. J Diabetes Res. 2019. PMID: 31781668 Free PMC article.
Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Kobayashi K, Toyoda M, Kimura M, Hatori N, Furuki T, Sakai H, Takihata M, Umezono T, Ito S, Suzuki D, Takeda H, Kanamori A, Degawa H, Yamamoto H, Machimura H, Mokubo A, Chin K, Obana M, Hishiki T, Aoyama K, Nakajima S, Umezawa S, Shimura H, Aoyama T, Sato K, Miyakawa M. Kobayashi K, et al. Diab Vasc Dis Res. 2019 Jan;16(1):103-107. doi: 10.1177/1479164118802759. Epub 2018 Oct 4. Diab Vasc Dis Res. 2019. PMID: 30284913 Free article.
Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
Tanaka A, Shimabukuro M, Okada Y, Sugimoto K, Kurozumi A, Torimoto K, Hirai H, Node K; PROCEED trial investigators. Tanaka A, et al. Cardiovasc Diabetol. 2020 Jun 13;19(1):85. doi: 10.1186/s12933-020-01065-w. Cardiovasc Diabetol. 2020. PMID: 32534578 Free PMC article.
234 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page